Arax Advisory Partners’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$77.6K Sell
4,759
-1,237
-21% -$23.2K ﹤0.01% 3005
2026
Q2
$90.5K Buy
5,996
+5,248
+702% +$91.6K ﹤0.01% 2809
2026
Q1
$14.3K Buy
748
+250
+50% +$5.43K ﹤0.01% 2261
2025
Q4
$10.9K Sell
498
-6,653
-93% -$120K ﹤0.01% 2419
2025
Q3
$86.8K Buy
7,151
+6,675
+1,402% +$90.4K ﹤0.01% 1583
2025
Q2
$8.87K Buy
476
+59
+14% +$1.17K ﹤0.01% 2014
2025
Q1
$7.99K Buy
417
+400
+2,353% +$11.7K ﹤0.01% 1628
2024
Q4
$613 Sell
17
-9
-35% -$304 ﹤0.01% 2287
2024
Q3
$1.1K Buy
26
+10
+63% +$424 ﹤0.01% 2217
2024
Q2
$645 Buy
+16
New +$668 ﹤0.01% 2286

Other funds holding TNDM

Arax Advisory Partners's TNDM Position: Q3 2026 in Review

Arax Advisory Partners reduced its Tandem Diabetes Care (TNDM) stake by 21% in Q3 2026, selling an estimated $23.2K and leaving 4,759 shares worth $77.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3005.

Arax Advisory Partners first reported a position in TNDM in Q2 2024 and has held it in 10 quarters since. The position peaked at $90.5K in Q2 2026. 267 funds tracked by Wall St. Rank hold TNDM as of Q3 2026.

  • Arax Advisory Partners held 4,759 shares of Tandem Diabetes Care worth $77.6K as of Q3 2026.
  • Arax Advisory Partners sold 1,237 Tandem Diabetes Care shares in Q3 2026, an estimated $23.2K.
  • Tandem Diabetes Care made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3005 holding.
  • Arax Advisory Partners first reported a position in Tandem Diabetes Care in Q2 2024 and has held it in 10 quarters since.
  • Arax Advisory Partners's Tandem Diabetes Care position peaked at $90.5K in Q2 2026.
  • 267 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.